ReviewCurrent HIV/AIDS reports2015
Enhancing our understanding of current therapies for hepatitis C virus (HCV).
Review in Current HIV/AIDS reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.Digestive diseases and sciences · 2016Pooled it
- Monoclonal antibody development against the Hepatitis C virus core protein enables rapid antigen detection.Scientific reports · 2026Article
- Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention.Statistical communications in infectious diseases · 2021Article
- Article
- Article
- Sec24C-Dependent Transport of Claudin-1 Regulates Hepatitis C Virus Entry.Journal of virology · 2017Article
- A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.Scientific reports · 2017Article
- Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors.The Journal of general virology · 2017Article
- Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.Addiction (Abingdon, England) · 2017Article
- Innate and Adaptive Immune Responses in Chronic HCV Infection.Current drug targets · 2017Review
- Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Therapeutics and clinical risk management · 2017Review
- Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy.Kidney international reports · 2016Article
- Hepatitis C treatment initiation in HIV-HCV coinfected patients.BMC infectious diseases · 2016Article
- Article
- Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.Clinical pharmacokinetics · 2015Review
- Chronic hepatitis C virus infection and lipoprotein metabolism.World journal of gastroenterology · 2015Review
- Actinobacteria from Termite Mounds Show Antiviral Activity against Bovine Viral Diarrhea Virus, a Surrogate Model for Hepatitis C Virus.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Editorial: Recent Advances in HBV and HCV Immunology.Frontiers in immunology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Great progress has been made in understanding the HCV genome and its molecular virology. This understanding has culminated in the development of direct-acting antiviral (DAA) agents targeting HCV viral proteins. Telaprevir (TVR) and boceprevir (BOC) were the first DAAs introduced for treatment of genotype 1 HCV in 2011; when used in combination with pegylated interferon (pegIFN) and ribavirin (RBV), these protease inhibitors improved efficacy in patients with chronic HCV infection compared to the traditional dual therapy. However, this combination was associated with adverse events that often led to early termination of therapy. In late 2013, the FDA approved a second wave of DAAs, sofosbuvir (SOF) and simeprevir (SMV). The use of SOF with SMV opened the door for IFN-free combination regimens. This combination was highly efficacious and well tolerated in patients with HCV genotype 1. Sofosbuvir and ledipasvir (LDV) fixed-dose oral combination (FDC) therapy, and paritaprevir/ritonavir, ombitasvir and dasabuvir ± RBV were recently approved, elevating sustained virologic response (SVR) rates to over 95 %. We are anticipating the approval of additional IFN-free regimens with comparable efficacy and tolerability but with the addition of pangenotypic coverage, fewer drug-drug interactions, and a high barrier to resistance. This review will summarize current management for chronic HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.